Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) have been assigned a consensus recommendation of “Buy” from the seventeen brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $86.85.

A number of equities analysts have weighed in on GBT shares. Zacks Investment Research raised Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 price target for the company in a research report on Friday, August 10th. Cowen reaffirmed a “buy” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a research report on Monday, August 13th. HC Wainwright set a $125.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Cantor Fitzgerald set a $96.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Finally, BidaskClub downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 19th.

A number of large investors have recently added to or reduced their stakes in the business. Focused Wealth Management Inc bought a new stake in shares of Global Blood Therapeutics during the 3rd quarter worth approximately $104,000. PNC Financial Services Group Inc. raised its stake in shares of Global Blood Therapeutics by 740.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the company’s stock worth $165,000 after purchasing an additional 3,835 shares in the last quarter. Rehmann Capital Advisory Group bought a new stake in shares of Global Blood Therapeutics during the 3rd quarter worth approximately $165,000. Tiverton Asset Management LLC bought a new stake in shares of Global Blood Therapeutics during the 2nd quarter worth approximately $166,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in shares of Global Blood Therapeutics during the 2nd quarter worth approximately $203,000.

Shares of GBT traded down $4.02 on Monday, hitting $42.66. The company’s stock had a trading volume of 4,168,610 shares, compared to its average volume of 1,565,665. Global Blood Therapeutics has a fifty-two week low of $30.15 and a fifty-two week high of $68.05. The firm has a market capitalization of $2.44 billion, a PE ratio of -15.45 and a beta of 3.65.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Tuesday, November 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.02. During the same period last year, the business earned ($0.66) earnings per share. As a group, research analysts anticipate that Global Blood Therapeutics will post -3.36 EPS for the current fiscal year.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Further Reading: What is the Coverage Ratio?

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.